BioSpace News Archive

Verastem Oncology announced that preclinical data will be presented in five posters at the American Association for Cancer Research Annual Meeting 2024 to be held on April 5-10 in San Diego, California.

AbCellera announced that its scientists will present four posters with data from its T-cell engager programs and platform at the American Association for Cancer Research Annual Meeting 2024, to be held April 5 to 10 at the San Diego Convention Center.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, announced four poster presentations at the American Association of Cancer Research Annual Meeting, to take place April 5 to 10, 2024 in San Diego, CA.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) today announced that interim efficacy and safety data from the Phase 2 TATCIST clinical trial evaluating FPI-2265 in patients with metastatic castration-resistant prostate cancer (mCRPC) has been selected for a clinical trial poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California.

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today reported financial results for the fourth quarter and year-ended December 31, 2023.

Foghorn® Therapeutics Inc. announced that preclinical data for its pipeline programs, including the first presentation of preclinical data for FHD-909, a potential first-in-class BRM selective inhibitor will be presented at the 2024 American Association for Cancer Research Annual Meeting being held April 5-10, 2024 in San Diego, California.

Nuvalent, Inc. (Nasdaq: NUVL) today announced upcoming preclinical data poster presentations further characterizing the preclinical profiles of its novel HER2-selective inhibitor, NVL-330, and novel ROS1-selective inhibitor, zidesamtinib (NVL-520), at the American Association for Cancer Research (AACR) Annual Meeting 2024 from April 5 – 10 in San Diego.

NX Development Corp. (NXDC) has achieved another milestone as we proudly announce the recent granting of orphan-drug status by the U.S. Food and Drug Administration (FDA) for Gleolan (aminolevulinic acid HCl).

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”) today announced that it will report financial results for the full year of 2023 ended December 31, 2023 and provide a business update on March 28, 2024.